Cargando…

Prognostic significance of clinicopathological factors in early breast cancer: 20 years of follow-up in a single-center analysis

BACKGROUND: To quantify the effect of traditional prognostic factors [nodal status, estrogen-receptor (ER), progesterone-receptor (PR), human epidermal growth factor receptor 2 (HER2)] on long-term outcome of patients with early breast cancer (EBC), treated in clinical practice over a period of abou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cocciolone, Valentina, Cannita, Katia, Calandrella, Maria Letizia, Ricevuto, Enrico, Baldi, Paola Lanfiuti, Sidoni, Tina, Irelli, Azzurra, Paradisi, Stefania, Pizzorno, Laura, Resta, Valter, Bafile, Alberto, Alesse, Edoardo, Tessitore, Alessandra, Ficorella, Corrado
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641109/ https://www.ncbi.nlm.nih.gov/pubmed/29069766 http://dx.doi.org/10.18632/oncotarget.18526

Ejemplares similares

Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations
por: Cocciolone, Valentina, et al.
Publicado: (2018)

New schedule of bevacizumab/paclitaxel as first‐line therapy for metastatic HER2‐negative breast cancer in a real‐life setting
por: Cannita, Katia, et al.
Publicado: (2016)

Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status
por: Irelli, Azzurra, et al.
Publicado: (2022)

The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A ‘hypothesis-generator’ study from clinical practice
por: Cortellini, Alessio, et al.
Publicado: (2018)

Circulating MicroRNAs as Prognostic and Therapeutic Biomarkers in Breast Cancer Molecular Subtypes
por: Zelli, Veronica, et al.
Publicado: (2020)

Role of the Molecular Tumor Board for the Personalized Treatment of Patients with Metastatic Breast Cancer: A Focus on the State of the Art in Italy
por: Irelli, Azzurra, et al.
Publicado: (2023)

"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study
por: Bruera, Gemma, et al.
Publicado: (2010)

Looking for A Place for Dose-Dense TMZ Regimens in GBM Patients: An Experience with MGMT Exploratory Evaluation
por: Napoleoni, Luca, et al.
Publicado: (2019)

Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)
por: Bruera, Gemma, et al.
Publicado: (2013)

Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain–Barré Syndrome
por: Cortellini, Alessio, et al.
Publicado: (2018)

Concurrent RAS and RAS/BRAF V600E Variants in Colorectal Cancer: More Frequent Than Expected? A Case Report
por: Zelli, Veronica, et al.
Publicado: (2022)

Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen
por: BRUERA, GEMMA, et al.
Publicado: (2014)

Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype
por: BRUERA, GEMMA, et al.
Publicado: (2013)

Effectiveness and Safety of Intensive Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, in Young-Elderly Metastatic Colorectal Cancer Patients
por: Bruera, Gemma, et al.
Publicado: (2013)

Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity
por: Cianci, G, et al.
Publicado: (2003)

Bioclinical Parameters Driving Decision-Making of Subsequent Lines of Treatment in Metastatic Castration-Resistant Prostate Cancer
por: Irelli, A., et al.
Publicado: (2014)

Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study
por: Ficorella, C, et al.
Publicado: (2004)

Multidisciplinary Management of Hepatocellular Carcinoma in Clinical Practice
por: Bruera, Gemma, et al.
Publicado: (2014)

Applications of Next Generation Sequencing to the Analysis of Familial Breast/Ovarian Cancer
por: Zelli, Veronica, et al.
Publicado: (2020)

Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease
por: Bruera, Gemma, et al.
Publicado: (2012)

Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis
por: Parisi, Alessandro, et al.
Publicado: (2019)

Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice
por: Cortellini, Alessio, et al.
Publicado: (2019)

Allostatic Load as an Insight into the Psychological Burden after Primary Treatment in Women with Breast Cancer: Influence of Physical Side Effects and Pain Perception
por: Irelli, Azzurra, et al.
Publicado: (2022)

Topical Menthol for Treatment of Chemotherapy-induced Peripheral Neuropathy
por: Cortellini, Alessio, et al.
Publicado: (2017)

What Is Known about Theragnostic Strategies in Colorectal Cancer
por: Parisi, Alessandro, et al.
Publicado: (2021)

Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study
por: Cortellini, Alessio, et al.
Publicado: (2020)

Physical Exercise and Quality of Life in Breast Cancer Survivors
por: VALENTI, Marco, et al.
Publicado: (2008)

Single‐institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non‐small cell lung cancer patients treated with first‐line chemotherapy
por: Cortellini, Alessio, et al.
Publicado: (2018)

Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non‐small cell lung cancer patients: A “hypothesis‐generator” preliminary report
por: Cortellini, Alessio, et al.
Publicado: (2019)

Multicentric retrospective analysis of platinum‐pemetrexed regimens as first‐line therapy in non‐squamous non‐small cell lung cancer patients: A “snapshot” from clinical practice
por: Cortellini, Alessio, et al.
Publicado: (2017)

Dose-finding study of oxaliplatin associated to capecitabine-based preoperative chemoradiotherapy in locally advanced rectal cancer
por: Bruera, Gemma, et al.
Publicado: (2018)

Serum Biomarkers Identification by Mass Spectrometry in High-Mortality Tumors
por: Tessitore, Alessandra, et al.
Publicado: (2013)

The Inflammatory Microenvironment in Hepatocellular Carcinoma: A Pivotal Role for Tumor-Associated Macrophages
por: Capece, Daria, et al.
Publicado: (2013)

Bioinformatics approach to predict target genes for dysregulated microRNAs in hepatocellular carcinoma: study on a chemically-induced HCC mouse model
por: Del Vecchio, Filippo, et al.
Publicado: (2015)

Role of exosomal microRNAs in cancer therapy and drug resistance mechanisms: focus on hepatocellular carcinoma
por: Zelli, Veronica, et al.
Publicado: (2022)

Classification of tumor types using XGBoost machine learning model: a vector space transformation of genomic alterations
por: Zelli, Veronica, et al.
Publicado: (2023)

Sex and Gender Influences on Cancer Immunotherapy Response
por: Irelli, Azzurra, et al.
Publicado: (2020)

Next-generation sequencing: recent applications to the analysis of colorectal cancer
por: Del Vecchio, Filippo, et al.
Publicado: (2017)

Emotional “Patient-Oriented” Support in Young Patients With I–II Stage Breast Cancer: Pilot Study
por: Di Giacomo, D., et al.
Publicado: (2018)

MicroRNAs in the DNA Damage/Repair Network and Cancer
por: Tessitore, Alessandra, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_a96q6mhc1lhq9mdc03doeg8hpt